AANEM News Express

AANEM News Express

AANEM Assists in Creation of New Codes to Account for Additional Services During Public Health Emergency

On September 8, 2020 the American Medical Association (AMA) published an update to the Current Procedural Terminology (CPT) code set that includes two new code additions for reporting medical services required by the public health response to the COVID-19 pandemic.  The two additions have been approved for immediate use.

The first addition, which will be most useful to AANEM members, is CPT code 99072—Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease.  This code was approved in response to measures that needed to be adopted by medical practices to help prevent the spread of the coronavirus, while safely providing patients with care.  AANEM worked with the AMA/Specialty Society RVS Update Committee (RUC) and the CPT Editorial Panel over the summer to aid in the development of this code. 

The second addition, CPT code 86413 allows for the quantitative measurements of SARS-CoV-2 antibodies, as opposed to a qualitative (positive/negative) assessment. The tests reported using this code can aid in investigating a person’s adaptive immune response to the virus.

AANEM continues to work with both the RUC and CPT to aid in the development and reimbursement of codes that impact our membership. If you have any questions or concerns about how these new additions to the CPT codes set will be used, you can email the policy department at policy@aanem.org.

View Related News Stories:


Recent AANEM News

Science News: Peripheral Nerve Compression Syndromes in Children

Science News: Monitoring Clinical Course and Treatment Response in Chronic Inflammatory Demyelinating Polyneuropathy During Routine Care

Patient Safety: EMG/NCS and Risk of Bleeding

Science News: Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis

Submit Your Abstract for the Myasthenia Gravis Foundation of America’s 2021 Scientific Session